Randomized, Multicenter, Open-label, Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Versus Chlorambucil in Patients 65 Years or Older With Treatment-naive Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Trial Profile

Randomized, Multicenter, Open-label, Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Versus Chlorambucil in Patients 65 Years or Older With Treatment-naive Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Jul 2017

At a glance

  • Drugs Ibrutinib (Primary) ; Chlorambucil
  • Indications Chronic lymphocytic leukaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms RESONATE-2
  • Sponsors Pharmacyclics
  • Most Recent Events

    • 25 Jun 2017 Results of adjusted comparison of data from RESONATE-2 study with data from CLLEAR and Lyon-Sud database presented at the 22nd Congress of the European Haematology Association.
    • 06 Jun 2017 Results assessing the impact of Ibrutinib vs chlorambucil on the immune system (n=80), presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 05 Jun 2017 Results published in an AbbVie media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top